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Background and Objectives
• Avelumab (an anti–PD-L1 
immune-checkpoint inhibitor) was 
recently approved in the United 
States, Europe, and Japan, 
among others, for the treatment of 
patients with metastatic Merkel 
cell carcinoma (mMCC)
• Safety and efficacy data are 
available from the JAVELIN 
Merkel 200: Part A trial of 88 
patients with previously treated 
mMCC (NCT02155647)
• The availability of increasingly 
maturing data from JAVELIN 
Merkel 200: Part A allows for the 
production (and subsequent 
validation) of overall survival (OS) 
extrapolations
• This analysis compares observed 
and extrapolated OS estimates 
from multiple data cuts using 





JAVELIN Merkel 200: Part A study publication: Kaufman et al., (2016) https://www.ncbi.nlm.nih.gov/pubmed/27592805
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Data
• This analysis compares observed 
and extrapolated OS estimates 
from 3 data cuts from Part A of the 
JAVELIN Merkel 200 trial
• Each data cut constitutes a 
different period of minimum follow-
up (MFU) for all patients:
– Data cut Sep-2016
• 12 months’ MFU
– Data cut Mar-2017
• 18 months’ MFU
– Data cut lock Sep-2017 
• 24 months’ MFU
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Kaplan-Meier plot of OS for each data cut
12 months’ MFU: Kaufman et al., (2018) https://www.ncbi.nlm.nih.gov/pubmed/29347993
18 months’ MFU: D’Angelo et al., (2018) http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.5_suppl.192
24 months’ MFU: Nghiem et al., (2018) https://meetinglibrary.asco.org/record/161628/abstract
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Methods
– The standard parametric survival 
models considered were the 
exponential, generalised gamma, 
Gompertz, log-logistic, log-normal, 
and Weibull (routinely considered 
to inform the estimation of OS in 
health technology assessment
– The spline-based models considered 
were natural restricted cubic spline 
models. The spline-based models were 
fitted with 1-3 internal knots using each 
of the 3 functional forms permitted by 
flexsurv. Knot locations were selected 
according to the percentiles of the log-
uncensored survival times
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• Standard parametric and spline-based models were fitted to OS data from 
Part A of JAVELIN Merkel 200 for each data cut
• All survival models were fitted in the statistical software R using the 
flexsurv package
• The selection of the best-fitting parametric survival model was determined 
through a combination of visual fit to the observed OS data, statistical 
goodness-of-fit (measured by Akaike’s information criterion [AIC]), and the 
plausibility of long-term extrapolation (based on clinical expert input)
R package flexsurv documentation: https://cran.r-project.org/web/packages/flexsurv/flexsurv.pdf
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Results
Extrapolation from September ‘16 (12 months’ MFU) data cut
5 Best-fitting standard parametric model: log-normal, best-fitting spline model: 1-knot odds
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Results
Extrapolation from March ‘17 (18 months’ MFU) data cut
6 Best-fitting standard parametric model: log-normal, best-fitting spline model: 1-knot odds
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Results
Extrapolation from September ‘17 (24 months’ MFU) data cut
7 Best-fitting standard parametric model: generalised gamma, best-fitting spline model: 1-knot odds
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Results
Summary
Assessment time 12 months 18 months 24 months
Observed survival
September 2016 (12 months’ MFU) data cut 51.8% 38.3% 38.3%
March 2017 (18 months’ MFU) data cut 50.8% 39.9% 34.3%
September 2017 (24 months’ MFU) data cut 50.1% 39.3% 35.8%
Assessment time Model AIC 12 months 18 months 24 months 60 months
Standard parametric survival
September 2016 (12 months’ MFU) data cut Log-normal 377.70 51.5% 39.3% 31.8% 12.4%
March 2017 (18 months’ MFU) data cut Log-normal 431.54 52.5% 40.7% 33.3% 13.8%
September 2017 (24 months’ MFU) data cut
Log-normal 455.31 54.1% 42.9% 35.8% 16.2%
Generalised gamma 454.68 52.3% 42.8% 37.0% 21.5%
Spline-based survival
September 2016 (12 months’ MFU) data cut 1-knot odds 379.26 51.5% 40.5% 34.1% 16.9%
March 2017 (18 months’ MFU) data cut 1-knot odds 432.29 50.7% 40.9% 35.0% 18.9%
September 2017 (24 months’ MFU) data cut 1-knot odds 453.81 50.8% 42.1% 37.1% 22.5%
8 Best-fitting models presented for each data cut.
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Conclusions
• Spline-based models provided a 
more accurate estimation of the 
observed 24-month OS based on 
extrapolation from earlier data 
than standard parametric 
approaches
• Longer-term survival estimates 
from the spline-based models 
were more aligned with clinical 
expectations of immunotherapy, 
ie, an emergent plateau in OS 
associated with the immune-
response effect of treatment
• Limitations and further research:
– Landmark or cure-based models 
may also reflect the expected 
immune-response effect in OS but 
require explicit assumptions about 
the estimation of long-term OS 
(such as the OS for cured patients, 
the prognostic importance of 
response, and the difference in the 
hazard of death by response)
– Longer-term data are required to 
validate OS extrapolations
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